Tey Marc, Mas Jesús, Pelfort Xavier, Monllau Joan Carles
Institut Català de Traumatologia i Medicina de l'Esport (ICATME), Hospital Dexeus de Barcelona, Barcelona, Spain.
Clínica Vistahermosa, Alicante, Spain.
Arthrosc Tech. 2015 Jan 19;4(1):e29-33. doi: 10.1016/j.eats.2014.10.002. eCollection 2015 Feb.
Microfracture, the current standard of care for the treatment of non-degenerative chondral lesions in the hip joint, is limited by the poor quality of the filling fibrocartilaginous tissue. BST-CarGel (Piramal Life Sciences, Laval, Quebec, Canada) is a chitosan-based biopolymer that, when mixed with fresh, autologous whole blood and placed over the previously microfractured area, stabilizes the blood clot and enhances marrow-triggered wound-healing repair processes. BST-CarGel has been previously applied in the knee, with statistically significant greater lesion filling and superior repair tissue quality compared with microfracture treatment alone. In this report we describe the application of BST-CarGel for the arthroscopic treatment of hip chondral lesions. Our preliminary data suggest that our BST-CarGel procedure provides high-quality repair tissue and therefore may be considered a safe, cost-efficient therapeutic choice for the treatment of hip chondral defects.
微骨折术是目前治疗髋关节非退行性软骨损伤的标准治疗方法，但填充的纤维软骨组织质量较差限制了其效果。BST-CarGel（加拿大魁北克拉瓦尔市派拉蒙生命科学公司）是一种基于壳聚糖的生物聚合物，当与新鲜自体全血混合并放置在先前微骨折的区域上时，可稳定血凝块并增强骨髓触发的伤口愈合修复过程。BST-CarGel先前已应用于膝关节，与单独的微骨折治疗相比，其在病变填充和修复组织质量方面具有统计学上的显著优势。在本报告中，我们描述了BST-CarGel在髋关节软骨损伤关节镜治疗中的应用。我们的初步数据表明，我们的BST-CarGel手术可提供高质量的修复组织，因此可被视为治疗髋关节软骨缺损的一种安全、经济高效的治疗选择。
